Interleukin-2 variant and use thereof

By designing the amino acid sequence of IL-2, improving binding force with β- and γ-chain dimer receptors and reducing binding force with Treg cell receptors, the existing IL-2 therapies are solved without effect at low doses. The problem of good and high-dose side effects has achieved more effective therapeutic effects and safety.

WO2024235281A1PCT designated stage expired Publication Date: 2024-11-21BEIJING JINGTAI TECH CO LTD

Patent Information

Application Number
PCT/CN2024/093573
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing IL-2 therapies cannot effectively activate effector T cells at low doses, and high doses use lead to serious side effects, mainly due to the differences in affinity of their receptors on different cells, resulting in limited therapeutic effects.

Method used

By redesigning the amino acid sequence of wild-type IL-2, IL-2 variants with increased binding force to the β- and γ-chain dimer receptors and decreased binding force to the Treg cell surface trimer receptors are obtained. Specifically, it includes amino acid substitution at positions 42 and 81 to improve the targeting of effector T cells.

Benefits of technology

Effective activation of effector T cells at low doses is achieved, reducing activation of Treg cells, reducing side effects, and improving the targeted and safe treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093573_21112024_PF_FP_ABST
    Figure CN2024093573_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided in the present disclosure are an interleukin-2 variant and the use thereof. In particular, provided in the present disclosure are an interleukin-2 (IL-2) variant protein or a fragment thereof. Compared with the amino acid sequence of a wild-type IL-2 as shown in SEQ ID NO: 1, the variant protein and the fragment thereof have amino acid substitutions at the 42nd and 81st sites. Also provided in the present disclosure are a derivative and conjugate containing said variant protein or fragment thereof of the present disclosure, an encoding nucleic acid molecule of said variant protein or fragment thereof or the derivative thereof, an expression vector, a host cell, and the use of same in drugs used for treatment or prevention of proliferative diseases or immune system diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Interleukin-2 variants and their applications Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to interleukin-2 variants and applications thereof. Background Art

[0002] IL-2 (also known as interleukin-2 or IL2) is an immune system regulator that plays a crucial role in the body's anti-tumor and anti-infection efforts. IL-2 can exert anti-tumor effects by stimulating the proliferation of effector T cells (Teffs). It can also suppress immune responses by activating regulatory T cells (Tregs).

[0003] To date, despite extensive research focused on the development of IL-2 drugs, these drugs have limited clinical efficacy. IL-2 has a dual regulatory mechanism in the body. At high doses, IL-2 can promote the proliferation of effector T cells, exerting anti-cancer activity. However, at low doses, IL-2 selectively activates regulatory T cells (Tregs). As regulatory targets of the immune system, Tregs are responsible for regulating various immune cells and inhibiting their ability to kill tumor cells.

[0004] This characteristic of IL-2 is mainly related to the expression of its receptors on different cells. The IL-2 receptor on the surface of regulatory T cells is mainly a trimeric receptor composed of α chain, β chain and γ chain, while effector T cells and NK cells express a dimeric receptor consisting of only β chain and γ chain. In addition, the affinity of trimeric receptors for IL-2 is about 100 times higher than that of dimeric receptors, which also explains why IL-2 therapy requires higher doses to be effective. Therefore, IL-2 therapy often requires higher dose levels to be effective, but high doses of IL-2 are often accompanied by serious side effects such as vascular permeability.

[0005] Therefore, it is very important for the therapeutic application of IL-2 to develop a drug that preferentially binds to cell surface β-chain and γ-chain dimer receptors at low doses, but does not bind to trimeric receptors on the surface of cells such as Treg, thereby promoting drug-targeted activation of effector T cells.

[0006] Summary of the Invention

[0007] In order to solve one of the above-mentioned technical problems existing in the prior art, the present invention redesigns the unstable structure on the non-active surface based on the crystal structure of wild-type IL-2 and the corresponding receptor, and obtains an IL-2 mutant with increased binding affinity to the cell surface β-chain and γ-chain dimer receptors and weaker binding affinity to the trimeric receptors on the surface of cells such as Treg cells.

[0008] According to one aspect of the present disclosure, a variant of interleukin-2 (IL-2) or a fragment thereof is provided, corresponding to the amino acid sequence of wild-type IL-2 shown in SEQ ID NO: 1, wherein the variant protein of IL-2 and its fragment have amino acid substitutions at positions 42 and 81.

[0009] Unless otherwise specified, the amino acid numbers disclosed herein correspond to the amino acid numbers in the amino acid sequence shown in SEQ ID NO: 1 (i.e., the natural sequential numbering from N-terminus to C-terminus relative to wild-type IL-2 shown in SEQ ID NO: 1).

[0010] In some embodiments, the phenylalanine (F) at position 42 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than phenylalanine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of F42P, F42R, F42H, F42V, F42N, F42S or F42I.

[0011] In some embodiments, the arginine (R) at position 81 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than arginine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of R81S, R81L, R81H, R81N, R81I, R81P, R81D or R81G.

[0012] In some embodiments, in addition to the amino acid substitutions at positions 42 and 81, the IL-2 variant protein or fragment thereof may have an amino acid substitution at at least one of positions 35, 37, 38, 62, 72, 80, and 87. In some embodiments, the IL-2 variant protein or fragment thereof may also have a substitution at one, two, three, four, five, six, or seven of positions 35, 37, 38, 62, 72, 80, and 87.

[0013] In some embodiments, the lysine (K) at position 35 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than lysine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of K35P, K35T, K35G or K35R.

[0014] In some embodiments, the threonine (T) at position 37 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than threonine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of T37A, T37K, T37D or T37N.

[0015] In some embodiments, the arginine (R) at position 38 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than arginine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of R38D, R38E, R38G, R38P, R38S or R3F.

[0016] In some embodiments, the glutamic acid (E) at position 62 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than glutamic acid. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of E62A, E62D, E62S, E62Q or E62H.

[0017] In some embodiments, the leucine (L) at position 72 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than leucine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of L72E, L72A, L72T, L72R, or L72S.

[0018] In some embodiments, the leucine (L) at position 80 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than leucine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among L80F or L80V.

[0019] In some embodiments, the serine (S) at position 87 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than arginine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution in S87E or S87D.

[0020] In some embodiments, the IL-2 variant protein or fragment thereof has an amino acid substitution at at least one of positions 39, 43, 45, 49, 65, 68, 69, 106, 107, and 129, in addition to the above-mentioned substitutions at positions 35, 37, 38, 42, 62, 72, 80, 81, and 87, corresponding to the amino acid sequence of wild-type IL-2 shown in SEQ ID NO: 1.

[0021] In some embodiments, the methionine (M) at position 39 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than methionine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among M39V, M39E or M39D.

[0022] In some embodiments, the lysine (K) at position 43 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than lysine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of K43L, K43E, K43V, or K43M.

[0023] In some embodiments, the tyrosine (Y) at position 45 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than tyrosine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among Y45S, Y45N, Y45M, Y45R or Y45A.

[0024] In some embodiments, the lysine (K) at position 49 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than lysine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of K49N.

[0025] In some embodiments, the proline (P) at position 65 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than proline. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among P65L, P65Y, P65S or P65R.

[0026] In some embodiments, the glutamic acid (E) at position 68 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than glutamic acid. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of E68G, E68R, E68P, E68K or E68A.

[0027] In some embodiments, the valine (V) at position 69 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than valine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of V69E, V69G, V69L or V69Y.

[0028] In some embodiments, the glutamic acid (E) at position 106 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than glutamic acid. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of E106D, E106H, E106G or E106Q.

[0029] In some embodiments, the tyrosine (Y) at position 107 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than tyrosine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of Y107R or Y107W.

[0030] In some embodiments, the isoleucine (I) at position 129 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than isoleucine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of I129Y.

[0031] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 35, 37, 38, 39, 42, 43, 62, 68, 72, 80, 81, 87 and 107. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 2, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 2. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 2, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 2.

[0032] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 35, 37, 38, 42, 43, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 107. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 3, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 3. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 3, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 3.

[0033] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 35, 37, 38, 39, 42, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 107. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 4, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 4. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 4, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 4.

[0034] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 35, 37, 38, 39, 42, 45, 62, 68, 69, 72, 80, 81, 87, 107 and 129. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 5, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 5. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 5, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 5.

[0035] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 35, 37, 38, 39, 42, 43, 62, 65, 72, 80, 81, 87, 106 and 129. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 6, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 6. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 6, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 6.

[0036] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 35, 37, 38, 39, 42, 43, 62, 65, 68, 69, 72, 80, 81, 87 and 107. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 7, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 7. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 7, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 7.

[0037] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 35, 37, 38, 39, 42, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87 and 106. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 8, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 8. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 8, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 8.

[0038] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 35, 37, 38, 39, 42, 43, 45, 49, 62, 65, 69, 72, 80, 81, 87, 106 and 129. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 9, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 9. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 9, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 9.

[0039] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 35, 37, 38, 39, 42, 43, 45, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 129. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 10, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 10. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 10, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence set forth in SEQ ID NO: 10.

[0040] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 35, 37, 38, 39, 42, 43, 62, 68, 72, 80, 81, 87 and 107. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 2, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 2. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 2, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 2.

[0041] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 35, 37, 38, 42, 43, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 107. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 3, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 3. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 3, or a substitution, deletion or insertion of one or more amino acid residues with the amino acid sequence shown in SEQ ID NO: 3.

[0042] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 35, 37, 38, 39, 42, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 107. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 4, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 4. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 4, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 4.

[0043] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 35, 37, 38, 39, 42, 45, 62, 68, 69, 72, 80, 81, 87, 107 and 129. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 5, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 5. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 5, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 5.

[0044] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 35, 37, 38, 39, 42, 43, 62, 65, 72, 80, 81, 87, 106 and 129. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 6, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 6. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 6, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 6.

[0045] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 35, 37, 38, 39, 42, 43, 62, 65, 68, 69, 72, 80, 81, 87 and 107. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 7, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 7. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 7, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 7.

[0046] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 35, 37, 38, 39, 42, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87 and 106. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 8, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 8. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 8, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 8.

[0047] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 35, 37, 38, 39, 42, 43, 45, 49, 62, 65, 69, 72, 80, 81, 87, 106 and 129. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 9, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 9. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 9, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 9.

[0048] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 35, 37, 38, 39, 42, 43, 45, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 129. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 10, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 10. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 10, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence set forth in SEQ ID NO: 10.

[0049] In some embodiments, in addition to the amino acid substitutions at positions 42 and 81, the IL-2 variant protein or fragment thereof may have a substitution at at least one of positions 27, 45, 65, and 85. In some embodiments, the IL-2 variant protein or fragment thereof may have a substitution at one, two, three, or four of positions 27, 45, 65, and 85.

[0050] In some embodiments, the glycine (G) at position 27 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than glycine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of G27R, G27E, or G27D.

[0051] In some embodiments, the tyrosine (Y) at position 45 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than tyrosine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of Y45K, Y45F, Y45G, Y45L or Y45R.

[0052] In some embodiments, the proline (P) at position 65 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than proline. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of P65S.

[0053] In some embodiments, the leucine (L) at position 85 of the variant protein of IL-2 or its fragment is replaced with other amino acid residues other than leucine. In some embodiments, the variant protein of IL-2 or its fragment may have any amino acid substitution in L85V or L85A. In some embodiments, corresponding to the amino acid sequence of wild-type IL-2 shown in SEQ ID NO: 1, in addition to the above-mentioned substitutions at positions 27, 42, 45, 65, 81 and 85, the variant protein of IL-2 or its fragment also has an amino acid substitution at at least one of positions 6, 9, 10, 12, 15, 16, 31, 44, 74, 75, 77, 80, 83, 86, 108, 127, 129, 130, 131, 132 and 133.

[0054] In some embodiments, corresponding to the amino acid sequence of wild-type IL-2 shown in SEQ ID NO: 1, in addition to the above-mentioned substitutions at positions 27, 42, 45, 65, 81 and 85, the IL-2 variant protein or fragment thereof further has an amino acid substitution at at least one of positions 4, 9, 10, 44, 74, 80, 86, 129 and 130.

[0055] In some embodiments, the variant protein of any of the foregoing IL-2 or a fragment thereof, the variant protein of IL-2 or a fragment thereof further has an amino acid substitution at at least one of positions 4, 6, 9, 10, 12, 15, 16, 31, 44, 74, 75, 77, 80, 83, 86, 108, 127, 129, 130, 131, 132 and 133 (e.g., 1, 2, 3, 4, 5, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22).

[0056] In some embodiments, the IL-2 variant protein or fragment thereof corresponds to the amino acid sequence of wild-type IL-2 as shown in SEQ ID NO: 1, in addition to the above-mentioned substitutions at positions 27, 42, 45, 65, 81 and 85, the IL-2 variant protein or fragment thereof further has an amino acid substitution at at least one of positions 6, 9, 10, 12, 15, 16, 31, 44, 74, 75, 77, 80, 83, 86, 108, 127, 129, 130, 131, 132 and 133 (e.g., position 1, 2, 3, 4, 5, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21).

[0057] In some embodiments, corresponding to the amino acid sequence of wild-type IL-2 shown in SEQ ID NO: 1, in addition to the above-mentioned substitutions at positions 27, 42, 45, 65, 81 and 85, the IL-2 variant protein or fragment thereof further has an amino acid substitution at at least one of positions 4, 9, 10, 44, 74, 80, 86, 129 and 130 (e.g., 1, 2, 3, 4, 5, 5, 7, 8 or 9 positions).

[0058] In some embodiments, the serine (S) at position 4 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than serine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of S4T.

[0059] In some embodiments, the serine (S) at position 6 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than serine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of S6E.

[0060] In some embodiments, the lysine (K) at position 9 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than lysine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among K9R or K9W.

[0061] In some embodiments, the threonine (T) at position 10 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than threonine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among T10I or T10M.

[0062] In some embodiments, the leucine (L) at position 12 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than leucine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among L12V or L12Q.

[0063] In some embodiments, the glutamic acid (E) at position 15 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than glutamic acid. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among E15G or E15R.

[0064] In some embodiments, the histidine (H) at position 16 of the IL-2 variant protein or fragment thereof is replaced with other non-histidine amino acid residues. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of H16Y.

[0065] In some embodiments, the tyrosine (Y) at position 31 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than tyrosine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of Y31N.

[0066] In some embodiments, the phenylalanine (F) at position 44 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than phenylalanine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among F44M or F44L.

[0067] In some embodiments, the glutamine (Q) at position 74 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than glutamine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of Q74H, Q74R or Q74S.

[0068] In some embodiments, the serine (S) at position 75 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than serine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of S75W.

[0069] In some embodiments, the asparagine (N) at position 77 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than asparagine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of N77K.

[0070] In some embodiments, the leucine (L) at position 80 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than leucine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among L80V or L80F.

[0071] In some embodiments, the arginine (R) at position 83 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than arginine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of R83I.

[0072] In some embodiments, the leucine (L) at position 86 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than leucine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among I86V or I86T.

[0073] In some embodiments, the alanine (A) at position 108 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than alanine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of A108T.

[0074] In some embodiments, the serine (S) at position 127 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than serine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of S127A.

[0075] In some embodiments, the isoleucine (I) at position 129 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than isoleucine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of I129Y or I129F.

[0076] In some embodiments, the serine (S) at position 130 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than serine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of S130Y or S130F.

[0077] In some embodiments, the threonine (T) at position 131 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than threonine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution of T131K or T131Q.

[0078] In some embodiments, the leucine (L) at position 132 of the IL-2 variant protein or fragment thereof is replaced with an amino acid residue other than serine. In some embodiments, the IL-2 variant protein or fragment thereof may have an amino acid substitution of L132W.

[0079] In some embodiments, the threonine (T) at position 133 of the IL-2 variant protein or fragment thereof is replaced with another amino acid residue other than threonine. In some embodiments, the IL-2 variant protein or fragment thereof may have any amino acid substitution among T133P, T133D or T133E.

[0080] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 6, 9, 15, 27, 42, 45, 65, 75, 77, 80, 81, 85, 108, 129, 130, 131 and 133. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 11, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 11. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 11, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 11.

[0081] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitution at one or more of positions 6, 9, 10, 12, 15, 27, 42, 44, 45, 65, 74, 75, 80, 81, 85, 86, 127, 130 and 131. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 12, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 12. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 12, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 12.

[0082] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 12, 15, 27, 31, 42, 44, 45, 65, 74, 75, 80, 81, 85, 86, 127, 131, 132, and 133. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 13, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 13. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 13, or a substitution, deletion, or insertion of one or more amino acid residues with the amino acid sequence set forth in SEQ ID NO: 13.

[0083] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 6, 12, 15, 16, 27, 31, 42, 44, 45, 65, 74, 77, 81, 83, 85, 127, 129, 130, 131 and 133. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 14, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 14. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 14, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 14.

[0084] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at one or more of positions 4, 9, 10, 27, 42, 44, 45, 65, 74, 80, 81, 85, 86, 129 and 130. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 15, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 15. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 15, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence set forth in SEQ ID NO: 15.

[0085] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 6, 9, 15, 27, 42, 45, 65, 75, 77, 80, 81, 85, 108, 129, 130, 131 and 133. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 11, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 11. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 11, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 11.

[0086] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 6, 9, 10, 12, 15, 27, 42, 44, 45, 65, 74, 75, 80, 81, 85, 86, 127, 130 and 131. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 12, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 12. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 12, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 12.

[0087] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 12, 15, 27, 31, 42, 44, 45, 65, 74, 75, 80, 81, 85, 86, 127, 131, 132 and 133. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 13, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 13. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 13, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 13.

[0088] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 6, 12, 15, 16, 27, 31, 42, 44, 45, 65, 74, 77, 81, 83, 85, 127, 129, 130, 131 and 133. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 14, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 14. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence shown in SEQ ID NO: 14, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO: 14.

[0089] In some specific embodiments, the IL-2 variant protein or fragment thereof has the above-mentioned amino acid substitutions at positions 4, 9, 10, 27, 42, 44, 45, 65, 74, 80, 81, 85, 86, 129 and 130. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 15, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence set forth in SEQ ID NO: 15. In some specific embodiments, the IL-2 variant protein or fragment thereof may have the amino acid sequence set forth in SEQ ID NO: 15, or have one or more amino acid residues substituted, deleted or inserted with the amino acid sequence set forth in SEQ ID NO: 15.

[0090] In some specific embodiments, the variant protein of IL-2 or its fragment described in any of the above items, except for the amino acid substitution site, the amino acid residues at other sites are the same as the amino acid residues at the corresponding sites of the wild-type IL-2 as shown in SEQ ID NO: 1.

[0091] In some specific embodiments, the variant protein of IL-2 or its fragment described in any of the above items has at least one of the following characteristics:

[0092] 1) Compared to the wild-type IL-2 shown in SEQ ID NO: 1, the IL-2 variant protein and its fragment have a reduced binding affinity to the human IL-2Rα monomer; in some specific embodiments, the IL-2 variant protein and its fragment binds to the human IL-2Rα monomer with a KD value greater than 10 nM (e.g., greater than 10 nM, greater than 20 nM, greater than 30 nM, greater than 40 nM, greater than 50 nM, greater than 100 nM, greater than 500 nM, greater than 1000 nM, greater than 10000 nM or greater), wherein the KD value is determined by surface plasmon resonance; in some specific embodiments, the IL-2 variant protein and its fragment do not bind to the human IL-2Rα monomer; in some specific embodiments, the KD value is determined by the method of Example 2 of this application;

[0093] 2) Compared to the wild-type IL-2 shown in SEQ ID NO: 1, the IL-2 variant protein and its fragment have increased binding affinity to the human IL-2Rβγ dimer; in some specific embodiments, the IL-2 variant protein and its fragment binds to the human IL-2Rβγ dimer with a KD value of less than 1 nM (e.g., less than 1 nM, less than 0.5 nM, less than 0.2 nM, less than 0.1 nM, less than 0.05 nM, less than 0.03 nM, less than 0.02 nM, less than 0.01 nM or less), wherein the KD value is determined by surface plasmon resonance; in some specific embodiments, the KD value of the IL-2 variant protein and its fragment binds to the human IL-2Rβγ dimer is less than 0.2 nM; in some specific embodiments, the KD value is determined by the method of Example 2 of this application;

[0094] 3) increasing the stimulation of MO7E cell proliferation compared to the wild-type IL-2 shown in SEQ ID NO: 1; in some specific embodiments, the stimulation of MO7E cell proliferation is determined by the method of Example 3 of the present application;

[0095] 4) reducing the stimulation of CTLL2 cell proliferation compared to the wild-type IL-2 shown in SEQ ID NO: 1; in some specific embodiments, the stimulation of CTLL2 cell proliferation is determined by the method of Example 3 of the present application;

[0096] 5) compared to the wild-type IL-2 shown in SEQ ID NO: 1, reducing the stimulation of Treg cell proliferation; in some specific embodiments, the stimulation of Treg cell proliferation is determined by the method of Example 5 of the present application; and / or

[0097] 6) increasing the stimulation of CD8+ T cell proliferation compared to wild-type IL-2 shown in SEQ ID NO: 1; in some specific embodiments, the stimulation of CD8+ T cell proliferation is determined by the method of Example 5 of the present application;

[0098] In some specific embodiments, the variant protein of IL-2 or a fragment thereof as described in any of the above items has low immunosuppression, low toxicity and / or high tumor suppression.

[0099] In some embodiments, the IL-2 variant protein or fragment thereof has an increased binding affinity to the β / γ chain dimer receptor of the IL-2 receptor (IL-2R) compared to wild-type IL-2. In some embodiments, the IL-2 variant protein or fragment thereof has an equivalent or decreased binding affinity to the α / β / γ chain trimer receptor of the IL-2R compared to wild-type IL-2.

[0100] According to another aspect of the present disclosure, a derivative of the IL-2 variant protein or fragment thereof of the present disclosure is provided, wherein the functional derivative includes: a fusion protein containing the IL-2 variant protein or fragment thereof; or a modified IL-2 variant protein or fragment thereof.

[0101] In some embodiments, the IL-2 variant protein or fragment thereof disclosed herein can form a fusion protein with an Fc fragment, albumin, etc. In some embodiments, the IL-2 variant protein or fragment thereof disclosed herein can be modified with polyethylene glycol (PEG), glycosylated, hydroxyethylated, or modified by removal of O-glycosylation, etc.

[0102] In one embodiment, the variant protein of IL-2 or its fragment that forms a fusion protein with an Fc fragment or albumin, and the modified variant protein of IL-2 or its fragment have a prolonged serum half-life compared to the variant protein of IL-2 or its fragment that does not form a fusion protein or is not modified.

[0103] According to another aspect of the present disclosure, a conjugate is provided, comprising:

[0104] A first domain comprising a domain of a variant protein of IL-2 or a fragment thereof disclosed herein, and

[0105] The second domain comprises an antigen binding domain or a shielding peptide domain.

[0106] In some embodiments, the antigen binding domain targets an antigen on a target cell. For example, the antigen binding domain can target an antigen presented on a tumor cell or in the environment of a tumor cell.

[0107] In some embodiments, the antigen-binding domain can be an antibody or an antigen-binding fragment thereof. In some embodiments, the antigen-binding domain can be selected from a polypeptide complex comprising an antibody heavy chain variable region and an antibody light chain variable region, ab, Fv, sFv, F(ab')2, scFv, sdAb, sdFv, nanobodies, peptibodies, etc. In some embodiments, the antigen-binding domain can be a monospecific antibody or a multispecific antibody (e.g., a bispecific antibody, etc.).

[0108] In other embodiments, the first domain is connected to the shielding peptide domain via a linker. In some embodiments, the shielding peptide can mask the activity of the variant protein of IL-2. In some embodiments, the linker is cut by enzymes in the human body. In some embodiments, the linker is a polypeptide linking fragment. In this case, the conjugate of the present invention exists in an inactive complete form (prodrug) in normal tissues. After entering the tumor tissue, the linker is cut by enzymes highly expressed in the tumor microenvironment, releasing the shielding peptide, restoring the activity of the variant protein of IL-2, and exerting a therapeutic effect.

[0109] According to another aspect of the present disclosure, a nucleic acid molecule is provided, which encodes the variant protein of IL-2 or a fragment thereof of the present disclosure.

[0110] According to yet another aspect of the present disclosure, a nucleic acid molecule is provided, which encodes the variant protein of IL-2 or a derivative of its fragment thereof.

[0111] According to another aspect of the present disclosure, a nucleic acid molecule is provided, which encodes the variant protein of IL-2 of the present disclosure or a fragment, derivative or conjugate thereof.

[0112] According to another aspect of the present disclosure, an expression vector is provided, which includes the above-mentioned nucleic acid molecule of the present disclosure.

[0113] According to another aspect of the present disclosure, a host cell is provided, which includes the above-mentioned nucleic acid molecules of the present disclosure. In some embodiments, the host cell can be a prokaryotic cell or a eukaryotic cell. In some embodiments, the host cell can be selected from bacteria, yeast cells or mammalian cells. In some embodiments, the host cell can be selected from Escherichia coli, human embryonic kidney cells (such as HEK 293 cells), African green monkey kidney (Vero) cells, Chinese hamster ovary (CHO) cells, etc.

[0114] According to another aspect of the present disclosure, a pharmaceutical composition is provided, comprising the IL-2 variant protein of the present disclosure or a fragment, derivative or conjugate thereof, and a pharmaceutically acceptable carrier.

[0115] According to another aspect of the present disclosure, a pharmaceutical composition is provided, comprising the IL-2 variant protein or fragment thereof of the present disclosure, and a pharmaceutically acceptable carrier.

[0116] According to another aspect of the present disclosure, provided is a variant protein of IL-2 or a fragment, derivative, conjugate, nucleic acid molecule, host cell or pharmaceutical composition thereof as described above for use as a drug; in some embodiments, the drug is used to treat or prevent a proliferative disease or an immune system disease.

[0117] According to another aspect of the present disclosure, a method for treating a proliferative disease or an immune system disease is provided, comprising administering to a subject in need thereof a therapeutically effective amount of any of the aforementioned IL-2 variant proteins or fragments, derivatives, conjugates, nucleic acid molecules, host cells or pharmaceutical compositions thereof.

[0118] According to another aspect of the present disclosure, provided is a use of the IL-2 variant protein or its fragment, derivative, conjugate, nucleic acid molecule, host cell or pharmaceutical composition in treating or preventing proliferative diseases or immune system diseases.

[0119] According to another aspect of the present disclosure, provided is a use of the IL-2 variant protein or fragment thereof in treating or preventing proliferative diseases or immune system diseases.

[0120] In some embodiments, any of the foregoing proliferative diseases may include, but are not limited to, bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, esophageal cancer, colorectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, bone cancer, and kidney cancer.

[0121] In some embodiments, the IL-2 variant protein or fragment thereof disclosed herein can stimulate the immune system. For example, the IL-2 variant protein or fragment thereof disclosed herein can increase the proliferation of T cells (particularly cytotoxic T cells) and promote the secretion of cytotoxic factors (e.g., interferon-gamma).

[0122] In some embodiments, the immune system disease may include, but is not limited to, diabetes, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), eczema, and asthma. BRIEF DESCRIPTION OF THE DRAWINGS

[0123] FIG1 shows the effect of the IL-2 variant protein disclosed herein on MO7E cell proliferation stimulation;

[0124] FIG2 shows the effect of the IL-2 variant protein disclosed herein on CTLL2 cell proliferation stimulation;

[0125] FIG3 shows the effect of the IL-2 variant protein disclosed herein on the pSTAT5 signal stimulation of MO7E cells;

[0126] FIG4 shows the effect of the IL-2 variant protein disclosed herein on the pSTAT5 signal stimulation of CTLL2 cells;

[0127] FIG5 shows the live cell flow cytometry sorting results of the IL-2 variant proteins disclosed herein;

[0128] FIG6 shows the flow cytometric sorting results of CD3+ cells by the IL-2 variant protein disclosed herein;

[0129] FIG7 shows the flow cytometric sorting results of CD4+ cells and CD8+ T cells by the IL-2 variant protein disclosed herein;

[0130] FIG8 shows the flow cytometry sorting results of Treg cells using the IL-2 variant protein disclosed herein;

[0131] FIG9 shows the effects of the IL-2 variant proteins disclosed herein on CD8+ T cell proliferation. In FIG9 , the columns of the same concentration, from left to right, are: WT IL-2 group, 2RBG-17 group, H9 group, medium group.

[0132] FIG10 shows the effects of the IL-2 variant proteins disclosed herein on CD8+ T cell proliferation. In FIG10 , the columns of the same concentration are, from left to right: WT IL-2 group, 2RBG-17 group, H9 group, and medium group.

[0133] FIG11 shows the effects of the IL-2 variant proteins disclosed herein on Treg cell proliferation. In FIG11 , the columns of the same concentration are, from left to right: WT IL-2 group, 2RBG-17 group, H9 group, and medium group. DETAILED DESCRIPTION

[0134] To make the objectives, technical solutions, and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the following examples. The specific embodiments described herein are intended only to illustrate the present invention and are not intended to limit the present invention in any way. In addition, in the following description, descriptions of known structures and technologies are omitted to avoid unnecessary confusion about the concepts of the present disclosure. Such structures and technologies are also described in many publications.

[0135] Human interleukin-2 (IL-2), also known as T-cell growth factor (TCGF), is located on chromosome 4 (4q27) and contains approximately 7 kb of sequence. Natural IL-2 consists of approximately 133 amino acids (SEQ ID NO: 1) and has a molecular weight of approximately 15 kDa. It was initially discovered that activated T cell culture fluid could promote T cell proliferation. Subsequently, the stimulatory factor in the culture fluid was purified and identified as IL-2.

[0136] IL-2 acts through the interleukin-2 receptor (IL-2R). IL-2R consists of three subunits: IL-2Rα (i.e., CD25), IL-2Rβ (i.e., CD122), and IL-2Rγ (i.e., CD132). These three subunits can form three receptor forms: the high-affinity receptor contains all three subunits IL-2Rα / β / γ; the intermediate-affinity receptor contains IL-2Rβ / γ; and the low-affinity receptor IL-2Rα. IL-2Rβ and IL-2Rγ are required for IL-2 to activate downstream signaling pathways. When IL-2 binds to both IL-2Rβ and IL-2Rγ simultaneously, the two receptor subunits form a heterodimer, phosphorylating STAT5 in the cell and translocating to the nucleus, leading to transcription and expression of the corresponding genes. IL-2Rα is not essential for signaling but can promote the binding of IL-2 to IL-2Rβ and IL-2Rγ.

[0137] IL-2Rγ is expressed in all immune cells. IL-2Rβ is expressed in CD8+ T cells, NK cells, and regulatory T cells, and its expression level increases after T cell activation. IL-2Rα is continuously highly expressed in regulatory T cells, but is transiently expressed in activated CD8+ T cells before being downregulated.

[0138] Wild-type IL-2 has three loop domains, namely amino acids 28 to 43 (loop 1), amino acids 73 to 88 (loop 2), and amino acids 111 to 118 (loop 3) of the amino acid sequence shown in SEQ ID NO: 1.

[0139] definition

[0140] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.

[0141] Unless the context clearly indicates otherwise, the expressions "a," "an," and "an" as used herein include plural references. For example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art. In addition, "plurality" refers to more than two, for example, 2, 3, 4, etc.

[0142] As used herein, the term "about" refers to a range of ±20% of the value that follows. In some embodiments, the term "about" refers to a range of ±10% of the value that follows. In some embodiments, the term "about" refers to a range of ±5% of the value that follows.

[0143] As used herein, the term "interleukin-2" or "IL-2" refers to natural IL-2 or IL-2 derivatives. As used herein, the terms "natural IL-2" and "natural interleukin-2" in the context of a protein or polypeptide refer to any naturally occurring or wild-type mammalian interleukin-2 amino acid sequence, including immature forms or precursor forms and mature forms. Non-limiting examples of GenBank accession numbers for amino acid sequences of natural mammalian interleukin-2 of various species include NP_032392.1 (Mus musculus, immature form), NP_001040595.1 (Macaca mulatta, immature form), NP_000577.2 (Human, precursor form), CAA01199.1 (Human, immature form), AAD48509.1 (Human, immature form), and AAB20900.1 (Human). In some embodiments, natural IL-2 is a precursor form of naturally occurring human IL-2. In some embodiments, the naturally occurring IL-2 is a mature form of naturally occurring human IL-2. In some embodiments, the amino acid sequence of naturally occurring human IL-2 comprises the amino acid sequence set forth in SEQ ID NO: 1. The amino acid numbering herein corresponds to the amino acid numbering in the amino acid sequence set forth in SEQ ID NO: 1.

[0144] The term "fragment" of a variant protein of IL-2 as used herein is intended to be understood as a variant protein of IL-2 that lacks one or more amino acids at the N-terminus and / or C-terminus, but still exhibits biological activity similar to that of the variant protein of IL-2 disclosed herein, i.e., an IL-2 mutant with increased binding to cell surface β-chain and γ-chain dimer receptors and weaker binding to trimeric receptors on the surface of cells such as Treg. A biological activity similar to that of the variant protein of IL-2 disclosed herein means that a fragment of the variant protein of IL-2 has at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the biological activity of the variant protein of IL-2. The activity of the variant protein of IL-2 and its fragments can be determined by methods known in the art.

[0145] As determined by assays known in the art (e.g., ELISA, SPR (e.g., BIAcore TMThe IL-2 variant protein or its fragment derivatives disclosed herein retain at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% of the function of the IL-2 variant protein or its fragment as measured by immunoprecipitation (e.g., immunoprecipitation, immunoprecipitation, and immunoprecipitation). It will be appreciated by those skilled in the art that the IL-2 variant protein or its fragment derivatives disclosed herein have increased binding affinity to cell surface β-chain and γ-chain dimer receptors but weaker binding affinity to trimeric receptors on the surface of cells such as Treg cells.

[0146] As used herein, the term "affinity" or "binding affinity" refers to the strength of the non-covalent interaction between a molecule (e.g., IL-2) and its receptor. Binding affinity can generally be expressed in terms of the dissociation constant (K D ) represents the dissociation constant (K D ) is the dissociation rate (k d ) and binding rate (k a ) ratio, namely K D =k d / k a Affinity can be measured by conventional methods known in the art, such as surface plasmon resonance (SPR).

[0147] The term "shielding peptide" as used herein refers to a modification of the IL-2 variant protein or fragment thereof disclosed herein to selectively mask the activity of the IL-2 variant protein in tissues and environments. In one embodiment, the shielding peptide is linked to the IL-2 variant protein or fragment thereof via a peptidase-cleavable linker. Such constructs can be used to treat cancer, where the level of proteases in the tumor microenvironment is greatly increased compared to non-tumor tissues. Selective cleavage of the cleavable linker in the tumor microenvironment allows the dissociation of the shielding peptide, thereby enabling the IL-2 variant protein or fragment thereof to act selectively in the tumor, but not in peripheral tissues, where its action may lead to undesirable side effects.

[0148] The term "linker" as used herein is a cleavable linker that facilitates drug release. Examples of cleavable linkers include acid-labile linkers (e.g., containing hydrazones), protease-sensitive linkers (e.g., peptidase-sensitive linkers), photolabile linkers, and disulfide-containing linkers.

[0149] Reference herein to "homology" or "percent identity (% identity)" between two sequences can be determined using techniques well known in the art. Some of the methods for determining identity are codified in publicly available computer programs. Sequence alignments and calculations of percent identity can be performed using, for example, The AlignX program of the LASERGENE bioinformatics computing software package (Invitrogen, Carlsbad, CA) or the MegAlign TM The procedure proceeds.

[0150] Alternatively, the determination of percent identity between two sequences can be determined using mathematical algorithms known to those skilled in the art. A non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA, 87:2264-2268, as modified by Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA, 90:5873-5877. Such algorithms have been incorporated into the NBLAST and XBLAST programs of Altschul et al. (1990) J. Mol. Biol., 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, for example, with score = 100 and wordlength = 12, to obtain nucleotide sequences homologous to the nucleotide sequences disclosed herein. To obtain gap alignments for comparison purposes, Gapped BLAST can be used as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search that detects distance relationships between molecules. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http: / / www.ncbi.nlm.nih.gov.

[0151] It will be understood that the variants of IL-2 and fragments thereof described herein may have additional conservative or non-essential amino acid substitutions that do not substantially affect the function of the molecule.

[0152] The term "amino acid" is intended to include all molecules, whether natural or synthetic, that include both an amino functional group and an acid functional group and that can be included in a polymer of naturally occurring amino acids. Exemplary amino acids include naturally occurring amino acids; their analogs, derivatives, and congeners; amino acid analogs with variant side chains; and all stereoisomers of any of the foregoing. As used herein, the term "amino acid" includes D-optical isomers or L-optical isomers and peptide mimetics.

[0153] "Conservative amino acid substitutions" are substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). For example, it is reasonable to expect that replacing a leucine moiety with an isoleucine or valine moiety alone, or performing similar amino acid substitutions with structurally related amino acids from the same family, will not significantly affect the binding or properties of the final molecule. By testing the specific activity of the polypeptide derivatives, it can be easily determined whether the amino acid changes result in functional peptides. Those skilled in the art can perform standard ELISA, surface plasmon resonance (SPR) or other binding assays to quantify the binding affinity of the IL-2 variant protein to its receptor.

[0154] The term "Fc region" or "Fc fragment" as used herein refers to the constant domain or constant region (CH) at the C-terminus of an immunoglobulin heavy chain or fragment thereof, which is a crystallizable fragment consisting of the CH2 and CH3 domains of Ig. As used herein, the term "Fc region" includes wild-type Fc regions and Fc region variants known in the art. The term "variant (human) Fc region" means that its amino acid sequence is different from the amino acid sequence of the wild-type (human) Fc region by at least one amino acid mutation. In some embodiments, the variant Fc region has at least one amino acid mutation, such as 1 to 10 amino acid mutations, compared to the wild-type Fc region. In some embodiments, the variant Fc region has 1 to 3 amino acid mutations compared to the wild-type Fc region.

[0155] The following examples and accompanying drawings are provided to facilitate understanding of the present invention. However, it should be understood that these examples and accompanying drawings are intended to illustrate the present invention only and are not intended to limit the present invention in any way. The actual scope of protection of the present invention is set forth in the claims. It should be understood that any modifications and variations may be made without departing from the spirit of the present invention.

[0156] Example

[0157] Reagents, experimental instruments and consumables used in the examples:

[0158] 1) IL-2 receptors were purchased from Beijing Biopsies (ACRO). The corresponding names and product numbers are as follows:

[0159] Human IL-2Rα / CD25 protein, Fc tag (HPLC-verified), ILA-H5251-100 μg;

[0160] Human IL-2Rβ & IL-2Rγ heterodimeric protein, Fc tag & Fc tag (MALS verified), ILG-H5254-100μg;

[0161] Human IL-2Rβ & IL-2Rα & IL-2Rγ proteins, Fc tag & Fc tag (MALS verified).

[0162] 2) Experimental instruments and consumables:

[0163] Biacore 8K plus, instrument purchasing company: Cytiva;

[0164] CM5 chip, item number: 29149603, purchasing company: Cytiva;

[0165] Multifunctional microplate reader, model: Varioskan LUX, company: Thermo;

[0166] BeyoGold TM All-white 96-well cell culture plate (flat bottom with lid, individually packaged); Product number: FCP968-80 pcs; Purchasing company: Beyotime;

[0167] 96-well plate, product number: 3799, company: CORNING;

[0168] 6-well plate, product number: 3471, company: CORNING;

[0169] Alexa 488Anti-Stat5(pY694), Catalog No.: 612598, Company: BD Pharmingen;

[0170] 4% paraformaldehyde fixative, product number: P0099-500mL, company: Beyotime;

[0171] 99.99% methanol, product number: M116118-500mL, company: Aladdin;

[0172] rhGM-CSF (CHO), CF (20UG), Catalog No.: 7954-GM-020 / CF, Company: R&D;

[0173] Luminescent Cell Viability Assay; Product No.: G7571; Purchasing company: Promega;

[0174] MO7E cells, purchased from BNCC;

[0175] CTLL2 cells, purchasing company: BNCC;

[0176] Cryopreserved human PBMC, product number: XC11211W, company: SAILYBIO

[0177] Culture medium RPMI 1640, purchased from Gibco;

[0178] Flow cytometer: SA3800, purchased from Sony;

[0179] PerCP / Cyanine5.5 anti-human CD3 (300430), PE / Cy7 anti-human CD4 (300512), Brilliant Violet510 TM Anti-human CD8 (344732), Brilliant Violet 605 TM Anti-human CD25 (302632), PE anti-human FOXP3 (320108), Alexa Anti-human Ki-67 (350510), Alexa 647 Mouse IgG1, κIsotype Ctrl (FC) (400130) was purchased from BioLegend;

[0180] eBioscience CD28 monoclonal antibody (CD28.2) (14-0289-82) and eBioscience CD3 monoclonal antibody (UCHT1) (14-0038-82) were purchased from eBioscience;

[0181] LIVE / DEAD TM Fixable purple dead cell stain kit for 405 nm excitation (L34964) was purchased from Invitrogen;

[0182] eBioscience TM Foxp3 / transcription factor staining buffer kit (cell permeabilization fixation staining) (00-5523-00) was purchased from eBioscience;

[0183] The pcDNA3.4 expression vector was purchased from Genscript;

[0184] KOP293 cell culture medium (K03252), KPM transfection buffer (K03125), TA-293 transfection reagent (K20001), KE-293 expression enhancer (K30001), and KT-Feed (50×) (K40001) transient transfection nutrient supplement were purchased from KairuiBiotech Zhuhai Kairui;

[0185] NaCL (7647-14-5) was purchased from Sigma-Aldrich (7647-14-5), and NaH2PO4·2H2O (13472-35-0) was purchased from Bidepharm;

[0186] Imidazole (288-32-4) was purchased from Accela.

[0187] 3) Data Analysis

[0188] The experimental data in this disclosure (such as repeated experiments, such as duplicate wells, multiple animals in the same dose group, etc.) are expressed as mean ± standard deviation, and component analysis was performed using t-test using SPSS software, with P < 0.05 indicating statistically significant differences between groups.

[0189] Example 1. Polypeptide preparation process and results

[0190] Phage display technology was used to screen for IL-2 variant proteins that have increased binding affinity to the β / γ chain dimer receptor of the IL-2 receptor (IL-2R) and decreased binding affinity to the α / β / γ chain trimer receptor compared to wild-type IL-2, as shown in Table 1 below.

[0191] Table 1. Amino acid sequences of wild-type IL-2 and its variant proteins

[0192] In order to further verify the binding of the screened IL variants to the receptor, the IL-2 variant protein was recombinantly expressed and prepared, and the wild-type human IL-2 was used as a control.

[0193] (1) Wild-type human IL-2 (abbreviated as WT-IL2 or WT IL-2) and IL-2 variant proteins were expressed separately and purified by using the 6-HIS tag at the C-terminus of the molecule.

[0194] (2) Nucleic acid sequences encoding WT IL-2 and various IL-2 variant proteins were obtained by total synthesis and subcloned into the pcDNA3.4 expression vector by enzymatic digestion. The accuracy of the final expression vector was confirmed by enzymatic digestion and sequencing. Transfection-grade plasmids were extracted using a plasmid extraction kit and transfected into mammalian HEK293 cells for transient expression. The proteins were purified by affinity chromatography.

[0195] (3) Cell recovery:

[0196] 1. Preheat a water bath to 37-40°C and prepare 10 mL of KOP293 culture medium in a centrifuge tube.

[0197] 2. Remove the cells from the liquid nitrogen tank or refrigerator and quickly place them in a preheated water bath. Use tweezers to hold the cryovial and shake it to ensure even heating.

[0198] 3. When the liquid in the cryovial is completely thawed, wipe the cryovial with alcohol for disinfection and pour the liquid into a centrifuge tube containing 10 mL of KOP293 culture medium.

[0199] 4. Centrifuge for 5 minutes (min represents minutes), remove the supernatant and obtain the precipitate.

[0200] 5. Resuspend the precipitate in KOP293 medium and inoculate into culture flasks for conventional cell culture.

[0201] After the cells recovered and grew for a period of time, 95% of the cells grew attached to the wall, the cells were in good condition, and the cells recovered successfully.

[0202] (4) Instantaneous transfer steps:

[0203] 1. Count the cells in a shaker and adjust the cell density to 2 × 10 6 pieces / mL.

[0204] 2. Place the cells with adjusted density in a new shake flask and continue shaking on a shaker for 10 minutes before transfection.

[0205] 3. Prepare the transfection system:

[0206] Prepare two 15 mL sterile centrifuge tubes. Add 5 mL of KPM transfection buffer and 100 μg of sterile plasmid DNA to one tube and gently pipette to mix. In the other tube, add 5 mL of KPM and 500 μL of TA-293 transfection reagent and gently pipette to mix.

[0207] 2) Transfer all the liquid in the centrifuge tube containing the transfection reagent to the centrifuge tube containing the plasmid and gently pipette to mix.

[0208] 3) The mixture was allowed to stand at room temperature for 10 minutes to prepare the plasmid-vector complex.

[0209] 4. Remove the cells from the constant temperature shaker, add the prepared plasmid-vector complex while shaking, and return to the CO2 constant temperature shaker for shaking culture.

[0210] 5. 24 hours after transfection, add 600 μL of 293 cell protein expression enhancer (KE-293) to increase product expression.

[0211] 6. Transient transfection nutrient additive (KT-Feed 50×) can increase the expression level of the product and can be added once 24 hours after transfection.

[0212] 7. Collect the supernatant and cells starting on the 6th day after transfection.

[0213] 8. Collect the cultured cells, disrupt the cells by ultrasound or enzymatic hydrolysis, and centrifuge to obtain the supernatant.

[0214] (5) Ni-NTA column affinity chromatography purification:

[0215] 1) Protein treatment: Cell culture medium contains EDTA. Dilute the sample three times with 1×PBS (pH=8.5) and filter through a 0.45 μm filter membrane (if the sample is too small, centrifuge at 15,000 rpm for 10 minutes).

[0216] 2) Equilibrate the column: Flow rate: 1 mL / min. Wash the packing three times with 5 column volumes of deionized water; then wash the packing twice with 5 column volumes of Buffer A (20 mM NaH2PO4, 0.5 M NaCl, pH 7.4);

[0217] (3) Washing: Wash the protein sample with 3 column volumes.

[0218] (4) Elution of target protein: Use 10% Buffer B (20 mM NaH2PO4, 0.5 M NaCL, 0.5 M imidazole pH 7.4, equivalent to 50 mmol / L imidazole) to wash the impurities until the baseline is stable, use 40% Buffer B to wash the target protein, and collect the protein peak.

[0219] (5) Pipette the high-concentration protein into a 1×PBS beaker and dialyze to obtain the target protein with higher purity.

[0220] The wild-type IL2 and IL variant proteins obtained in this step will be used in subsequent experiments.

[0221] Example 2. Determination of the affinity of wild-type human IL-2 and IL-2 variant proteins to different receptors.

[0222] In this example, surface plasmon resonance (SPR) experiments were used to determine the affinity of wild-type human IL-2 (WT IL-2) and IL-2 variant proteins (2RBG-17 and Phage1) obtained in Example 1 to the receptor monomer IL-2Rα (ACRO, ILA-H5251), the dimeric receptor IL-2Rβγ (ACRO, ILG-H5254), and the trimeric receptor IL-2Rαβγ (ACRO, ILG-H5257). Meanwhile, H9 (Levin, A., Bates, D., Ring, A. et al. Exploiting a natural conformational switch to engineer an interleukin-2'superkine'. Nature 484, 529–533 (2012). https: / / doi.org / 10.1038 / nature10975) was used as a Yang Shen control, which has APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHFDPRDVVSNINVVVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT (SEQ ID NO: 16); D014 (inactive sequence) was used as a negative reference control, which has the sequence of MKEIQLKAEHALLDAQMLVQQFDEGNWELMQDHLTNLGVFYNEIVADMNQKPEYSKAAVAKLEHAANELERAFTNPTEEGQAELGEIANELITIAQSLISTVHHHHHH (SEQ ID NO: 17).

[0223] The target proteins (i.e., the aforementioned IL-2Rα, dimeric receptor IL-2Rβγ, and trimeric receptor IL-2Rαβγ) were coupled using a CM5 chip. The coupling concentration was 5 μg / mL, and the amount of coupled protein was approximately 5000 RU. The test substances were diluted in 10 gradients starting from 5 μg / mL, and the affinities of different test substances with different IL-2Rs were tested.

[0224] The affinity test results of wild-type human IL-2 and some IL-2 variant proteins are shown in Tables 2 to 4 below.

[0225] Table 2. Affinity determination results of wild-type human IL-2 and its variants to IL-2Rα monomer

[0226] From the results in Table 2 , it can be seen that neither 2RBG-17 nor Phage1 binds to IL-2Rα.

[0227] Table 3. Affinity determination results of wild-type human IL-2 and its variants for the dimeric receptor IL-2Rβγ

[0228] From the results in Table 3 , it can be seen that the affinity of 2RBG-17 and Phage1 for IL-2Rβγ dimer is better than that of wild-type IL-2.

[0229] Table 4. Affinity determination results of wild-type human IL-2 and its variants for the trimeric receptor IL-2Rαβγ

[0230] From the results in Table 4 , it can be seen that the affinity of 2RBG-17 and Phage1 for the trimeric receptor IL-2Rβγ is comparable to that of wild-type IL-2.

[0231] Through the above affinity tests, it was found that the variant proteins of IL-2 screened by the present disclosure do not bind to IL-2Rα. The affinity of the variant proteins of IL-2 screened by the present disclosure to the IL-2Rβγ dimer receptor is better than that of WT IL-2. In addition, the affinity of the variant proteins of IL-2 screened by the present disclosure to the IL-2Rαβγ trimer receptor is the same as that of WT IL-2. 2RBG17 and Phage1 maintain an affinity for the IL-2Rαβγ trimer receptor similar to that of WT IL-2 while greatly improving the affinity with the IL-2Rβγ dimer receptor, and can exert a better biased activation function.

[0232] Example 3. Cell proliferation test

[0233] To test whether the IL2 variants screened in this disclosure can stimulate the corresponding cell surface receptors, this example used MO7E cells and CTLL2 cells for cell proliferation experiments. H9 (Levin, A., Bates, D., Ring, A. et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484, 529–533 (2012). https: / / doi.org / 10.1038 / nature10975) was used as a positive control, having the sequence shown in SEQ ID NO: 16; D014 (SEQ ID NO: 17, an inactive polypeptide) was used as a negative control.

[0234] 1. MO7E cell proliferation experiment

[0235] MO7E cells are a human giant cell leukemia cell line that expresses IL-2Rβγ dimer receptors on their surface. These cells can grow independently of cytokines, but their growth is slow. IL-2 can stimulate cell proliferation by binding to its surface dimer.

[0236] Experimental steps:

[0237] 1) Cell culture: MO7E cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum, 1% penicillin-streptomycin mixture, 8 ng / mL GM-CSF, and in a 37°C, 5% CO2 incubator.

[0238] 2) Cell plating: Take pre-cultured MO7E cells, wash them three times with culture medium (RPMI 1640 + 10% fetal bovine serum + 1% double antibody), count them with a cell counter, and adjust the volume to 4×10 5 The concentration of cells / mL was 20K / well (50 μL / well) and inoculated into a full white 96-well plate;

[0239] 3) Test substance dilution and sample addition: The test substance was diluted in basal medium to eight concentrations: 20, 4, 0.8, 0.16, 0.032, 0.0064, 0.00128, and 0 nM. Different concentrations of test substance were added to a 96-well plate, and 50 μL / well was mixed with cells. The cell-free group was supplemented with experimental medium as a blank control. Three replicates were set up and incubated at 37°C, 5% CO2 incubator for 72 hours (hours).

[0240] 4) Proliferation assay: After incubating cells with different concentrations of the test substance for 72 hours, the cells were Luminescent Cell Viability Assay Kit experimental process, using a microplate reader chemiluminescence method to read and record the value of each plate. According to the test, the IL-2 variant protein disclosed in the present invention has enhanced the stimulation of MO7E cell proliferation compared with wild-type IL-2.

[0241] The results of the detection of the stimulating effect of some representative variants on MO7E cell proliferation are shown in Table 5 and Figure 1 below.

[0242] Table 5. Effects of IL-2 variant proteins on MO7E cell proliferation

[0243] Note: EC50 in Table 5 refers to the concentration of the test substance required for 50% of MO7E cells to survive in the MO7E cell proliferation assay. Specifically, the cell viability at each test substance concentration in step 3) was first calculated based on the numerical value obtained in step 4), and the calculation method was: cell viability = [(At-Ab) / (Ac-Ab)×100%]; At: absorbance value of the wells in the experimental group (i.e., the experimental group containing cell culture medium, test solution, and test substance); Ab: absorbance value of the wells in the blank control group (i.e., the control group containing cell culture medium, test solution, and no test substance, with a dosing time of 0 and a treatment time of 0, and no cells); Ac: absorbance value of the wells in the negative control group (i.e., the control group containing cell culture medium, test solution, and no test substance, with a test substance concentration of 0); then, using GraphPad graphing software, set to the XY table module, input the test substance concentration and the corresponding cell viability, and then analyze. The software automatically fits and calculates the test drug concentration required for 50% cell survival, which is the EC50 of MO7E. The value is negatively correlated with the binding ability / affinity of the test substance and the dimeric receptor IL-2Rβγ.

[0244] As shown in Table 5 and Figure 1, both 2RBG-17 and Phage1 have a greater effect on the proliferation of MO7E cells than wild-type IL-2. Compared with the WT IL-2 group, 2RBG-17 increased the proliferation of MO7E cells by more than tenfold, reaching the same level as Yangshen H9 cells.

[0245] 2.CTLL-2 Cell Proliferation Assay

[0246] CTLL-2 cells are cloned from cytotoxic T cells of C57BL / 6 mice. They express the IL-2Rαβγ trimeric receptor on their cell surface. Their growth is dependent on IL-2 stimulation. IL-2 can bind to their surface trimeric receptors and stimulate cell proliferation. The experimental steps are as follows:

[0247] 1) Cell culture: CTLL2 cells were cultured in 1640 medium containing 10% fetal bovine serum, 1% double-antibody (penicillin-streptomycin mixture), 1% HEPES, 1% sodium pyruvate, and β-mercaptoethanol at 37°C in a 5% CO2 incubator.

[0248] 2) Cell plating: CTLL-2 cells cultured in advance were washed three times with a culture medium containing 10% fetal bovine serum, 1% double-antibody (penicillin-streptomycin mixture), HEPES, β-mercaptoethanol, and sodium pyruvate. The cells were counted using a cell counter and the volume was adjusted to 2×10 5 The concentration of cells / mL was 10K / well (50 μL / well) and inoculated into a full white 96-well plate;

[0249] 3) Test substance dilution and sample addition: The test substance was diluted in basal medium to eight concentrations: 20, 4, 0.8, 0.16, 0.032, 0.0064, 0.00128, and 0 nM. Different concentrations of test substance were added to a 96-well plate, and 50 μL / well was mixed with cells. The cell-free group was supplemented with experimental medium as a blank control. Three replicates were set up and incubated at 37°C, 5% CO2 incubator for 48 h.

[0250] 4) Proliferation assay: After incubating cells with different concentrations of the test substance for 48 hours, The experimental process of the Luminescent Cell Viability Assay Kit is to read and record the value of each plate using a microplate reader chemiluminescence method. The IL-2 variant protein disclosed in the present invention has been tested to reduce the stimulation of CTLL2 cell proliferation compared with wild-type IL-2.

[0251] The results of the stimulation of CTLL2 cell proliferation by some representative variants disclosed herein are shown in Table 6 and Figure 2 below.

[0252] Table 6. Effects of IL-2 variant proteins on CTLL2 cell proliferation

[0253] Note: In Table 6, EC50 refers to the concentration of the test substance required for 50% of the CTLL2 cells to survive in the above CTLL2 cell proliferation assay. Specifically, the cell viability at each test substance concentration in step 3) was first calculated based on the values ​​obtained in step 4), and the calculation method was: cell viability = [(At-Ac) / (Ac-Ab)×100%], where At: absorbance value of the wells in the experimental group (i.e., the experimental group containing cell culture medium, test solution, and test substance); Ab: absorbance value of the wells in the blank control group (i.e., the control group containing cell culture medium, test solution, and no test substance, with a dosing time of 0 and a treatment time of 0, and no cells); Ac: absorbance value of the wells in the negative control group (i.e., the control group containing cell culture medium, test solution, and no test substance, with a test substance concentration of 0). Then, using GraphPad graphing software, set to the XY table module, input the test substance concentration and the corresponding cell viability, and then analyze. The software automatically fits and calculates the test drug concentration required for 50% cell survival, which is the EC50 of CTLL2. The value is negatively correlated with the binding ability / affinity of the test substance and the trimeric receptor IL-2Rαβγ.

[0254] From the results in Table 6 and Figure 2 , it can be seen that compared with WT IL-2, the activation of CTLL2 cells by 2RBG-17 was reduced by 550 times, and the activation of CTLL2 cells by Phage1 was also reduced by 150 times, while the activation of CTLL-2 cells by the Yangshen control H9 was similar to that of the WT IL-2 group.

[0255] Example 4. Detection of phosphorylation signaling pathway

[0256] IL-2 can activate downstream phosphorylation pathways after binding to functional receptors, so the functional activity of IL-2 protein can be detected by pSTAT5 signaling.

[0257] 1. Detection of phosphorylation pathway in MO7E cells:

[0258] Experimental steps:

[0259] 1) Cell culture: MO7E cells were cultured in 1640 medium containing 10% fetal bovine serum, 1% penicillin-streptomycin mixture, and 8 ng / mL GM-CSF in a 37°C, 5% CO2 incubator.

[0260] 2) Cell treatment and plating: Pre-cultured MO7E cells were taken and washed three times with RPMI 1640 basal medium (RPMI 1640 + 10% fetal bovine serum + 1% double antibody). The stimulants in the cell culture medium were removed, and then the cells were counted using a cell counter and adjusted to 4×10 6 The concentration of cells / mL was 50 μL / well and plated in a 96-well plate. At this time, there were about 200,000 cells per well.

[0261] 3) Cell Stimulation: The test substances and the Yangshen control (H9) were diluted with RPMI 1640 basal medium to six concentrations (i.e., 10,000 ng / mL, 1,000 ng / mL, 100 ng / mL, 10 ng / mL, 1 ng / mL, 0.1 ng / mL, 50 μL / well), mixed with the cells, and incubated at 37°C in a 5% CO2 incubator for 20 minutes to stimulate the cells;

[0262] 4) Cell fixation: After 20 minutes of stimulation, add an equal volume of 1.5% formaldehyde fixative to each well (100 μL / well), vortex mix, and react at room temperature for 10 minutes to fix the cells and stop stimulation;

[0263] 5) Cell Permeabilization: After fixation, centrifuge at 400 g for 5 minutes, discard the supernatant, and resuspend the cells in 99%-100% pre-chilled methanol at 100 μL / well. Incubate at 4°C for 30 minutes to permeabilize the cells.

[0264] 6) Washing: Wash the treated cells three times with FACS buffer;

[0265] 7) Cell staining: Dilute the fluorescent antibody 1:5 with FACS buffer, resuspend the cells in 50 μL / well, and incubate in the dark at room temperature for 2 hours;

[0266] 8) Repeat step 6);

[0267] 9) Analyze the data after the flow cytometer test.

[0268] Compared to WT IL-2, the IL-2 variant proteins disclosed herein enhance the stimulation of pSTAT5 signals in MO7E cells, and the test results of some IL-2 variant proteins are better than those of H9. The test results of some exemplary IL-2 variant proteins are shown in Table 7 and Figure 3 below.

[0269] Table 7. Effects of IL-2 variant proteins on pSTAT5 signal stimulation in MO7E cells

[0270] Note: In Table 7, EC50 refers to the concentration of the test substance required to induce 50% of the phosphorylation of the cell pSTAT5 signaling pathway in the above MO7E cell phosphorylation pathway detection experiment. Specifically, the cell phosphorylation rate at each test substance concentration in step 3) was first calculated based on the numerical value obtained in step 9), and the calculation method was: cell phosphorylation rate = [(At-Ab) / (Ac-Ab)] × 100%, At: the mean fluorescence intensity of the experimental group (i.e., the wells containing cell culture medium, test solution, and test substance); Ac: the mean fluorescence intensity of the wells of the negative control group (i.e., the wells containing cell culture medium, test solution, and no test substance (test substance concentration is 0)); Ab: the mean fluorescence intensity of the wells of the blank control group (i.e., the wells containing cell culture medium, test solution, and no test substance). Then, according to the GraphPad graphing software, set it to the XY table module, input the test substance concentration and the corresponding cell phosphorylation rate, and then analyze. The software automatically fits and calculates the test substance concentration required for 50% of MO7E cells to phosphorylate pSTAT5, that is, the EC50 value in Table 7 above.

[0271] As shown in Table 7 and Figure 3, 2RBG-17 stimulated the pSTAT5 signal in MO7E cells by approximately 50-fold compared to WT IL-2. Phage1 also had a superior cell activation effect on MO7E cells compared to WT IL-2.

[0272] 2. CTLL2 cell phosphorylation pathway detection:

[0273] Experimental steps:

[0274] 1) Cell culture: CTLL2 cells were cultured in 1640 medium containing 10% fetal bovine serum, 1% double-streptomycin (penicillin-streptomycin mixture), HEPES, β-mercaptoethanol, sodium pyruvate, and IL-2 in a 37°C, 5% CO2 incubator.

[0275] 2) Cell treatment and plating: Pre-cultured CTLL2 cells were taken and washed three times with RPMI 1640 basal medium (RPMI 1640 + 10% fetal bovine serum + 1% double antibody + β-mercaptoethanol + sodium pyruvate). The cells were cultured in a cell incubator overnight to remove stimulants in the cell culture medium. The cells were then counted using a cell counter and adjusted to 4 × 10 6 The concentration of cells / mL was 50 μL / well and plated in a 96-well plate. At this time, there were about 200,000 cells per well.

[0276] 3) Cell Stimulation: The test substances and Yangshen control (H9) were diluted with RPMI 1640 basal medium to eight concentrations (i.e., 1000 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, 0.001 nM, 0.0001 nM, 50 μL / well), mixed with the cells, and incubated at 37°C in a 5% CO2 incubator for 15-20 minutes to stimulate the cells;

[0277] 4) Cell fixation: After stimulation, add an equal volume of 4% formaldehyde fixative to each well (100 μL / well), vortex to mix, and react at room temperature for 10 minutes to fix the cells and stop stimulation;

[0278] 5) Cell Permeabilization: After fixation, centrifuge at 400 g for 5 minutes, discard the supernatant, and resuspend the cells in 99% to 100% pre-chilled methanol at 100 μL / well. Incubate at 4°C in the dark for 30 minutes to achieve cell permeabilization.

[0279] 6) Washing: Wash the treated cells three times with FACS buffer;

[0280] 7) Cell staining: Dilute the fluorescent antibody 1:5 with FACS buffer, resuspend the cells in 50 μL / well, and incubate in the dark at room temperature for one hour;

[0281] 8) Repeat step 6);

[0282] 9) Analyze the data after the flow cytometer test.

[0283] Compared with WT IL-2, the IL-2 variant proteins disclosed herein reduce the stimulation of pSTAT5 signals in CTLL2 cells. The test results of some exemplary IL-2 variant proteins are shown in Table 8 and Figure 4 below.

[0284] Table 8. Effects of IL-2 variant proteins on pSTAT5 signaling in CTLL2 cells

[0285] Note: In Table 8, EC50 refers to the concentration of the test substance required to induce 50% of the phosphorylation of the pSTAT5 signaling pathway in the above CTLL2 cell phosphorylation pathway detection experiment. Specifically, the cell phosphorylation rate at each test substance concentration in step 3) was first calculated based on the numerical value obtained in step 9), and the calculation method was: cell phosphorylation rate = [(At-Ab) / (Ac-Ab)] × 100%, At: the mean fluorescence intensity of the experimental group (i.e., the wells containing cell culture medium, test solution, and test substance); Ac: the mean fluorescence intensity of the wells of the negative control group (i.e., the wells containing cell culture medium, test solution, and no test substance (test substance concentration is 0)); Ab: the mean fluorescence intensity of the wells of the blank control group (i.e., the wells containing cell culture medium, test solution, and no test substance). Then, according to the GraphPad graphing software, set it to the XY table module, input the test substance concentration and the corresponding cell phosphorylation rate, and then analyze. The software automatically fits and calculates the test substance concentration required for 50% of the CTLL2 cells to phosphorylate pSTAT5, that is, the EC50 value in Table 8.

[0286] From the results in Table 8 and Figure 4 , it can be seen that compared with WT IL-2, the stimulation of CTLL2 pSTAT5 signal by 2RBG-17 and Phage1 was significantly weaker.

[0287] Example 5 Effect of IL-2 variant protein on CD8+ / Treg cell proliferation

[0288] This example tests the effects of IL-2 variants on T cell proliferation stimulation in human PBMCs, as well as on CD8+ T cell proliferation, Treg cell proliferation, and IFN-γ release. The experimental procedure is as follows:

[0289] For PBMC recovery, first use 0.5μg / 0.2μg concentration of CD3 / CD28 antibodies and adjust the cell concentration to 1×10 7 / ml, pre-stimulated for 3 days, and then washed the cells twice with 1640 basal medium (RPMI 1640 + 10% fetal bovine serum + 1% double antibody) to remove the pre-stimulation antibody, and adjusted the cell concentration to 1×10 6 / ml, 50 μl / well was added to a 96-well plate. The blank control (medium), WT IL-2-treated group, and test substance group were diluted to different concentrations (1nM, 0.1nM, 0.01nM) and mixed with the cells at 50 μl / well. The 96-well cell culture plate was placed in a cell culture incubator and cultured for 6 days. On the third day of culture, half of the medium was replaced and cultured for another three days.

[0290] 1) Collect drug-treated cells to detect cell viability and count, add 2×10 5 cells, then use LIVE / DEAD TM Fixable Purple Dead Cell Staining Kit, add Live / Dead according to the instructions TM The dye was incubated at 4°C for 30 min;

[0291] 2) Wash the cells once with FACS staining buffer (PBS containing 2% FBS), centrifuge at 2000 rpm for 5 minutes, and discard the supernatant. Then, add 50 μL of mixed antibodies (CD3 / CD4 / CD8 / CD25) to each well and incubate at 4°C for 30 minutes.

[0292] 3) After incubation, the cells were washed with FACS staining buffer, centrifuged at 2000 rpm for 5 min, and the supernatant was discarded. TM After cells were fixed and permeabilized using the Foxp3 staining buffer and the kit, 50 μL of mixed antibodies (Foxp3 / Ki67) were added to the corresponding samples and incubated at 4°C for 30 min;

[0293] 4) Wash the cells once with FACS staining buffer (PBS containing 2% FBS), centrifuge at 2000 rpm for 5 minutes, discard the supernatant, and resuspend the cells in 200 μL FACS staining buffer for FACS analysis.

[0294] Live cells were sorted by flow cytometry, and CD4 cells, CD8+T cells, and Treg cells (CD25+Foxp3) were sorted and counted according to different surface receptors, and the Ki67 fluorescence intensity of CD8+T cells and Treg cells was detected.

[0295] The flow cytometric grouping results are shown in Figures 5 to 8. Figure 5 shows the sorting of live cells from all cells, Figure 6 shows the sorting of CD3 cells from live cells, Figure 7 shows the sorting of CD4-positive cells and CD8-positive cells from CD3 cells, and Figure 8 shows the sorting of Treg cells from CD4-positive cells.

[0296] The results of CD8+ T cell proliferation are shown in Figure 9. As shown in Figure 9, the number of CD8+ T cells in 2RBG-17 was superior to that of WT IL-2 at both 0.01 nM and 0.1 nM, and particularly at 0.1 nM, it was also superior to the Yangshen control H9. The number of CD8+ T cells in Phage1 was also superior to that of WT IL-2 at both 0.01 nM and 0.1 nM.

[0297] Ki67 is an antigen associated with proliferating cells. Its function is closely related to mitosis and is essential for cell proliferation. A higher Ki67 fluorescence intensity indicates a higher number of cells in the mitotic phase. We further examined the Ki67 fluorescence intensity in CD8+ T cells and Treg cells to confirm the proliferation status of T cells. The results are shown in Figures 10 and 11.

[0298] As shown in Figures 10 and 11, at a concentration of 0.1 nM, the Ki67 fluorescence signal intensity of CD8+ T cells in the 2RBG-17 group far exceeded that in the WT IL-2 group and the Yangshen H9 group. This indicates that the 2RBG-17 group had more CD8+ T cells in the proliferation cycle, which is more conducive to the tumor-killing effect of CD8+ T cells. In addition, the Ki67 fluorescence signal of Treg cells in the 2RBG-17 group was weaker than that in the WT IL-2 and Yangshen H9 groups, indicating that the number of Treg cells in the proliferation phase in the 2RBG-17 group was less than that in the WT IL-2 and H9 groups, and that it can cause less immunosuppression and toxicity than WT IL-2.

[0299] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. Any technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.

Claims

1. A variant protein of interleukin-2 (IL-2) or a fragment thereof, It is characterized in that Relative to the amino acid sequence of wild-type IL-2 shown in SEQ ID NO: 1, the IL-2 variant protein and fragments thereof have amino acid substitutions at positions 42 and 81, wherein the amino acid positions are numbered according to the amino acid sequence of SEQ ID NO:

1.

2. The variant protein of IL-2 or a fragment thereof according to claim 1, in, The phenylalanine (F) at position 42 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than phenylalanine; Preferably, the IL-2 variant protein or fragment thereof has any one of the amino acid substitutions of F42P, F42R, F42H, F42V, F42N, F42S or F42I.

3. The variant protein of IL-2 or a fragment thereof according to claim 1 or 2, in, The arginine (R) at position 81 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than arginine; Preferably, the IL-2 variant protein or fragment thereof has any one of the amino acid substitutions R81S, R81L, R81H, R81N, R81I, R81P, R81D or R81G.

4. The variant protein of IL-2 or a fragment thereof according to any one of claims 1 to 3, wherein the variant protein of IL-2 or a fragment thereof further has an amino acid substitution at at least one of positions 35, 37, 38, 62, 72, 80 and 87; Preferably, the IL-2 variant protein or fragment thereof, in, 1) The lysine (K) at position 35 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than lysine. Preferably, the IL-2 variant protein or a fragment thereof has any one of K35P, K35T, K35G or K35R amino acid substitutions; 2) the threonine (T) at position 37 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than threonine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions of T37A, T37K, T37D or T37N; 3) the arginine (R) at position 38 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than arginine, preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions R38D, R38E, R38G, R38P, R38S or R3F; 4) the glutamic acid (E) at position 62 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than glutamic acid. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions E62A, E62D, E62S, E62Q or E62H; 5) The leucine (L) at position 72 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than leucine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions of L72E, L72A, L72T, L72R or L72S; 6) the leucine (L) at position 80 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than leucine, preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions L80F or L80V; and / or 7) The serine (S) at position 87 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than arginine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions S87E or S87D.

5. The variant protein of IL-2 or a fragment thereof according to any one of claims 1 to 4, further comprising an amino acid substitution at at least one of positions 39, 43, 45, 49, 65, 68, 69, 106, 107 and 129; Optionally, the variant protein of IL-2 or a fragment thereof, in: 1) The methionine (M) at position 39 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than methionine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions of M39V, M39E or M39D; 2) the lysine (K) at position 43 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than lysine, preferably, the IL-2 variant protein or a fragment thereof has any one of K43L, K43E, K43V or K43M amino acid substitutions; 3) The tyrosine (Y) at position 45 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than tyrosine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions of Y45S, Y45N, Y45M, Y45R or Y45A; 4) the lysine (K) at position 49 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than lysine, preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of K49N; 5) The proline (P) at position 65 of the IL-2 variant protein or a fragment thereof is replaced with another non-proline amino acid residue. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions of P65L, P65Y, P65S or P65R; 6) The glutamic acid (E) at position 68 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than glutamic acid. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions E68G, E68R, E68P, E68K or E68A; 7) the valine (V) at position 69 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than valine, preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions of V69E, V69G, V69L or V69Y; 8) The glutamic acid (E) at position 106 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than glutamic acid. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions E106D, E106H, E106G or E106Q; 9) The tyrosine (Y) at position 107 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than tyrosine, preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions Y107R or Y107W; and / or 10) The isoleucine (I) at position 129 of the IL-2 variant protein or a fragment thereof is replaced with an amino acid residue other than isoleucine. Preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of I129Y; Optionally, the variant protein of IL-2 or a fragment thereof, wherein: 1) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 35, 37, 38, 39, 42, 43, 62, 68, 72, 80, 81, 87 and 107; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 35, 37, 38, 39, 42, 43, 62, 68, 72, 80, 81, 87 and 107; Preferably, the IL-2 variant protein or fragment thereof has an amino acid sequence as shown in SEQ ID NO: 2, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 2, or having a substitution, deletion or insertion of one or more amino acid residues with the amino acid sequence as shown in SEQ ID NO: 2; 2) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 35, 37, 38, 42, 43, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 107; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 35, 37, 38, 42, 43, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 107; preferably, the variant protein of IL-2 or a fragment thereof has the amino acid sequence shown in SEQ ID NO: 3, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence shown in SEQ ID NO: 3, or a substitution, deletion, or substitution of one or more amino acid residues with the amino acid sequence shown in SEQ ID NO:

3. loss or insertion; 3) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 35, 37, 38, 39, 42, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 107; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 35, 37, 38, 39, 42, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 107; Preferably, the IL-2 variant protein or fragment thereof has an amino acid sequence as shown in SEQ ID NO: 4, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 4, or has a substitution, deletion or insertion of one or more amino acid residues with the amino acid sequence as shown in SEQ ID NO: 4; 4) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 35, 37, 38, 39, 42, 45, 62, 68, 69, 72, 80, 81, 87, 107 and 129; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 35, 37, 38, 39, 42, 45, 62, 68, 69, 72, 80, 81, 87, 107 and 129; Preferably, the IL-2 variant protein or fragment thereof has an amino acid sequence as shown in SEQ ID NO: 5, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 5, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence as shown in SEQ ID NO: 5; 5) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 35, 37, 38, 39, 42, 43, 62, 65, 72, 80, 81, 87, 106 and 129; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 35, 37, 38, 39, 42, 43, 62, 65, 72, 80, 81, 87, 106 and 129; Preferably, the IL-2 variant protein or fragment thereof has an amino acid sequence as shown in SEQ ID NO: 6, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 6, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence as shown in SEQ ID NO: 6; 6) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 35, 37, 38, 39, 42, 43, 62, 65, 68, 69, 72, 80, 81, 87 and 107; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 35, 37, 38, 39, 42, 43, 62, 65, 68, 69, 72, 80, 81, 87 and 107; Preferably, the IL-2 variant protein or fragment thereof has an amino acid sequence as shown in SEQ ID NO: 7, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 7, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence as shown in SEQ ID NO: 7; 7) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 35, 37, 38, 39, 42, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87 and 106; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 35, 37, 38, 39, 42, 45, 49, 62, 65, 68, 69, 72, 80, 81, 87 and 106; Preferably, the variant protein of IL-2 or a fragment thereof has an amino acid sequence as shown in SEQ ID NO: 8, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 8, or has a substitution, deletion or insertion of one or more amino acid residues with the amino acid sequence as shown in SEQ ID NO: 8; 8) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 35, 37, 38, 39, 42, 43, 45, 49, 62, 65, 69, 72, 80, 81, 87, 106 and 129; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 35, 37, 38, 39, 42, 43, 45, 49, 62, 65, 69, 72, 80, 81, 87, 106 and 129; Preferably, the variant protein of IL-2 or a fragment thereof has an amino acid sequence as shown in SEQ ID NO: 9, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 9, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence as shown in SEQ ID NO: 9; and / or 9) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 35, 37, 38, 39, 42, 43, 45, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 129; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 35, 37, 38, 39, 42, 43, 45, 62, 65, 68, 69, 72, 80, 81, 87, 106 and 129; Preferably, the IL-2 variant protein or fragment thereof has the amino acid sequence shown in SEQ ID NO: 10, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence shown in SEQ ID NO: 10, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO:

10.

6. The variant protein of IL-2 or a fragment thereof according to any one of claims 1 to 5, wherein the variant protein of IL-2 or a fragment thereof further has an amino acid substitution at at least one of positions 27, 45, 65 and 85; Optionally, the variant protein of IL-2 or a fragment thereof, in, 1) The glycine (G) at position 27 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than glycine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions G27R, G27E or G27D; 2) the tyrosine (Y) at position 45 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than tyrosine, preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions of Y45K, Y45F, Y45G, Y45L or Y45R; 3) the proline (P) at position 65 of the IL-2 variant protein or a fragment thereof is replaced with another non-proline amino acid residue, preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of P65S; and / or 4) The leucine (L) at position 85 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than leucine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions L85V or L85A.

7. The variant protein of IL-2 or a fragment thereof according to any one of claims 1 to 6, further comprising an amino acid substitution at at least one of positions 4, 6, 9, 10, 12, 15, 16, 31, 44, 74, 75, 77, 80, 83, 86, 108, 127, 129, 130, 131, 132 and 133; Optionally, the variant protein of IL-2 or a fragment thereof has an amino acid substitution at at least one of positions 6, 9, 10, 12, 15, 16, 31, 44, 74, 75, 77, 80, 83, 86, 108, 127, 129, 130, 131, 132 and 133; or the variant protein of IL-2 or a fragment thereof has an amino acid substitution at at least one of positions 4, 9, 10, 44, 74, 80, 86, 129 and 130; Optionally, the variant protein of IL-2 or a fragment thereof, in: 1) The serine (S) at position 4 of the IL-2 variant protein or a fragment thereof is replaced with other non-serine amino acid residues. Preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of S4T; 2) the serine (S) at position 6 of the IL-2 variant protein or a fragment thereof is replaced with other non-serine amino acid residues. Preferably, the IL-2 variant protein or a fragment thereof may have an amino acid substitution of S6E; 3) the lysine (K) at position 9 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than lysine, preferably, the IL-2 variant protein or a fragment thereof has any one of K9R or K9W amino acid substitutions; 4) the threonine (T) at position 10 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than threonine. Preferably, the IL-2 variant protein or a fragment thereof has any one of T10I and T10M amino acid substitutions; 5) The leucine (L) at position 12 of the IL-2 variant protein or a fragment thereof is replaced with an amino acid residue other than leucine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions L12V or L12Q; 6) The glutamic acid (E) at position 15 of the variant protein of IL-2 or its fragment is replaced by other amino acids other than glutamic acid; Preferably, the variant protein of IL-2 or a fragment thereof has any one of E15G or E15R amino acid substitutions; 7) The histidine (H) at position 16 of the IL-2 variant protein or a fragment thereof is replaced with other non-histidine amino acid residues. Preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of H16Y; 8) The tyrosine (Y) at position 31 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than tyrosine. Preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of Y31N; 9) the phenylalanine (F) at position 44 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than phenylalanine, preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions of F44M or F44L; 10) The glutamine (Q) at position 74 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than glutamine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions of Q74H, Q74R or Q74S; 11) The serine (S) at position 75 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than serine. Preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of S75W; 12) The asparagine (N) at position 77 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than asparagine. Preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of N77K; 13) The leucine (L) at position 80 of the IL-2 variant protein or a fragment thereof is replaced with an amino acid residue other than leucine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions L80V or L80F; 14) the arginine (R) at position 83 of the IL-2 variant protein or a fragment thereof is replaced with other amino acid residues other than arginine, preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of R83I; 15) The leucine (L) at position 86 of the IL-2 variant protein or a fragment thereof is replaced with an amino acid residue other than leucine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions I86V or I86T; 16) the alanine (A) at position 108 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than alanine, preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of A108T; 17) The serine (S) at position 127 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than serine. Preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of S127A; 18) The isoleucine (I) at position 129 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than isoleucine. Preferably, the IL-2 variant protein or a fragment thereof has any one of I129Y or I129F amino acid substitutions; 19) The serine (S) at position 130 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than serine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions S130Y or S130F; 20) The threonine (T) at position 131 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than threonine. Preferably, the IL-2 variant protein or a fragment thereof has any one of T131K and T131Q amino acid substitutions; 21) The leucine (L) at position 132 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than serine, preferably, the IL-2 variant protein or a fragment thereof has an amino acid substitution of L132W; and / or 22) The threonine (T) at position 133 of the IL-2 variant protein or a fragment thereof is replaced with another amino acid residue other than threonine. Preferably, the IL-2 variant protein or a fragment thereof has any one of the amino acid substitutions T133P, T133D or T133E; Optionally, the variant protein of IL-2 or a fragment thereof, wherein: 1) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 6, 9, 15, 27, 42, 45, 65, 75, 77, 80, 81, 85, 108, 129, 130, 131 and 133; optionally, the IL- 2 or a fragment thereof having the amino acid substitutions at positions 6, 9, 15, 27, 42, 45, 65, 75, 77, 80, 81, 85, 108, 129, 130, 131 and 133; Preferably, the IL-2 variant protein or fragment thereof has an amino acid sequence as shown in SEQ ID NO: 11, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 11, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence as shown in SEQ ID NO: 11; 2) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 6, 9, 10, 12, 15, 27, 42, 44, 45, 65, 74, 75, 80, 81, 85, 86, 127, 130 and 131; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 6, 9, 10, 12, 15, 27, 42, 44, 45, 65, 74, 75, 80, 81, 85, 86, 127, 130 and 131; Preferably, the IL-2 variant protein or fragment thereof has an amino acid sequence as shown in SEQ ID NO: 12, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 12, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence as shown in SEQ ID NO: 12; 3) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 12, 15, 27, 31, 42, 44, 45, 65, 74, 75, 80, 81, 85, 86, 127, 131, 132 and 133; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 12, 15, 27, 31, 42, 44, 45, 65, 74, 75, 80, 81, 85, 86, 127, 131, 132 and 133; Preferably, the IL-2 variant protein or fragment thereof has an amino acid sequence as shown in SEQ ID NO: 13, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 13, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence as shown in SEQ ID NO: 13; 4) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 6, 12, 15, 16, 27, 31, 42, 44, 45, 65, 74, 77, 81, 83, 85, 127, 129, 130, 131 and 133; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 6, 12, 15, 16, 27, 31, 42, 44, 45, 65, 74, 77, 81, 83, 85, 127, 129, 130, 131 and 133; Preferably, the variant protein of IL-2 or a fragment thereof has an amino acid sequence as shown in SEQ ID NO: 14, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence as shown in SEQ ID NO: 14, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence as shown in SEQ ID NO: 14; and / or 5) the variant protein of IL-2 or a fragment thereof has an amino acid substitution at one or more of positions 4, 9, 10, 27, 42, 44, 45, 65, 74, 80, 81, 85, 86, 129 and 130; alternatively, the variant protein of IL-2 or a fragment thereof has the amino acid substitution at positions 4, 9, 10, 27, 42, 44, 45, 65, 74, 80, 81, 85, 86, 129 and 130; Preferably, the IL-2 variant protein or fragment thereof has the amino acid sequence shown in SEQ ID NO: 15, or an amino acid sequence having at least 85% sequence identity with the amino acid sequence shown in SEQ ID NO: 15, or has one or more amino acid residues substituted, deleted or inserted with the amino acid sequence shown in SEQ ID NO:

15.

8. The variant protein of IL-2 or a fragment thereof according to any one of claims 1 to 7, which has at least one of the following characteristics: 1) Compared with the wild-type IL-2 shown in SEQ ID NO: 1, the IL-2 variant protein or its fragment has a reduced binding affinity to the human IL-2Rα monomer; optionally, the KD value of the IL-2 variant protein or its fragment binding to the human IL-2Rα monomer is greater than 10nM, wherein the KD value is determined by surface plasmon resonance; optionally, the IL-2 variant protein or its fragment does not bind to the human IL-2Rα monomer; 2) Compared with the wild-type IL-2 shown in SEQ ID NO: 1, the IL-2 variant protein or its fragment has an increased binding affinity to the human IL-2Rβγ dimer; optionally, the KD value of the IL-2 variant protein or its fragment binding to the human IL-2Rβγ dimer is less than 1 nM, wherein the KD value is determined by surface plasmon resonance; optionally, the The KD value of the IL-2 variant protein or fragment thereof binding to the human IL-2Rβγ dimer is less than 0.2 nM; 3) increasing the stimulation of MO7E cell proliferation compared to wild-type IL-2 shown in SEQ ID NO: 1; 4) reducing the stimulation of CTLL2 cell proliferation compared to wild-type IL-2 shown in SEQ ID NO: 1; 5) reducing the stimulation of Treg cell proliferation compared to wild-type IL-2 shown in SEQ ID NO: 1; and / or 6) Compared with the wild-type IL-2 shown in SEQ ID NO: 1, it increases the stimulation of CD8+ T cell proliferation.

9. A derivative of a variant protein of IL-2 or a fragment thereof according to any one of claims 1 to 8, in, The derivatives include: 1) A fusion protein of a variant protein of IL-2 or a fragment thereof according to any one of claims 1 to 8; or 2) A modified variant protein or fragment of IL-2 according to any one of claims 1 to 8; Optionally, the fusion protein of the variant protein of IL-2 or its fragment comprises the variant protein of IL-2 or its fragment and an Fc fragment or albumin; Optionally, the modified IL-2 variant protein or fragment thereof, the modification includes modification by polyethylene glycol, modification by glycosylation, modification by hydroxyethylation or modification by removal of O-glycosylation; Preferably, the fusion protein containing the IL-2 variant protein or fragment thereof or the modified IL-2 variant protein or fragment thereof has a prolonged serum half-life compared to the variant protein or fragment thereof without forming a fusion protein or unmodified IL-2.

10. A conjugate, wherein the conjugate include: A first domain, which comprises the variant protein or fragment of the IL-2 according to any one of claims 1 to 8, and a second domain comprising an antigen binding domain or a shielding peptide domain; Preferably, the antigen binding domain specifically targets an antigen on a target cell, and more preferably is an antibody or an antigen binding fragment thereof; Preferably, the first domain is connected to the shielding peptide domain via a linker; preferably, the shielding peptide can mask the activity of the variant protein of IL-2; more preferably, the linker can be cleaved by an enzyme in the human body. 11 . A nucleic acid molecule encoding the variant protein of IL-2 or a fragment thereof according to any one of claims 1 to 8 , the derivative according to claim 9 , or the conjugate according to claim 10 .

12. An expression vector comprising the nucleic acid molecule according to claim 11.

13. A host cell, comprising the nucleic acid molecule according to claim 11 or the expression vector according to claim 12; Preferably, the host cell is a prokaryotic cell or a eukaryotic cell; Optionally, the host cell is selected from bacteria, yeast cells or mammalian cells; Optionally, the host cell is selected from Escherichia coli, human embryonic kidney cells, African green monkey kidney cells or Chinese hamster ovary cells.

14. A pharmaceutical composition comprising the variant protein or fragment thereof according to any one of claims 1 to 8, the derivative according to claim 9 or the conjugate according to claim 10, and a pharmaceutically acceptable carrier.

15. Use of the variant protein or fragment thereof according to any one of claims 1 to 8, the derivative according to claim 9, the conjugate according to claim 10, the nucleic acid molecule according to claim 11, the host cell according to claim 13 or the pharmaceutical composition according to claim 14 in the preparation of a drug for treating or preventing a proliferative disease or an immune system disease; Optionally, the proliferative disease include: bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, esophageal cancer, colorectal cancer, stomach cancer, prostate cancer, blood cancer, skin cancer, bone cancer and / or kidney cancer; and / or The immune system disorders include diabetes, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, eczema and / or asthma.

Citation Information

Patent Citations

  • CD122 with altered ICD STAT signaling

    CN115038453A

  • Novel interleukin-2 and use thereof

    US20210221863A1

  • IL2 Agonists

    US20210292386A1

  • Modified Interleukin 2 (IL-2) Polypeptides, Conjugates and Uses Thereof

    US20220289806A1

  • Novel interleukin 2 and use thereof

    WO2020057646A1

Cited By

  • Masked multifunctional proteins

    WO2026158523A1